Viatris Innovation GmbH
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-35
RECRUITING1
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +19.9 months). See all sponsors →
Open Viatris Innovation GmbH on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| OPUS-2 NCT05672576 |
P3 | Active, not recruiting | Lupus Erythematosus, Systemic | 451 | 2026-12-31 (+18 mo) |
| OPUS-1 NCT05648500 |
P3 | Active, not recruiting | Lupus Erythematosus, Systemic | 470 | 2027-03-31 (+20 mo) |
| SOS-AMI NCT04957719 |
P3 | Enrolling by invitation | Acute Myocardial Infarction | 25000 | 2027-07 (+41 mo) |
| LUMIOS NCT07201129 |
P3 | Recruiting | Nephritis, Lupus; Lupus Erythematosus, Systemic | 300 | 2029-08 |
| OPUS OLE NCT06475742 |
P3 | Enrolling by invitation | Lupus Erythematosus, Systemic | 680 | 2032-09 (+58 mo) |